Anavex Life Sciences Corp (AVXL)

[RedShoulder]

Peter, thanks again for you outstanding analysis:

Conclusions

The improvents in all four parts of the UPDRS are consistent across all measures and are well separated from placebo.

Parts I and II are much more easily affected than parts III and IV, yet the most significant therapeutic effect can be found in the latter measures for Blarcamesine. A very or the only effective drug.

This status of Blarcamesine is corroborated by the results from $ANVS ‘s Posiphen with lack of significant response in parts III and IV.

Parts III and IV show very stable characteristic for the patients over time. Nevertheless, Blarcamesine (mean of improvement of the sample) can improve them over 10 times better than current drugs. All in short duration of 14 weeks.

Parkinson’s is etiologically connected to atrophy of motor neurons in the brain and periphery. By restoring or ameliorating the motor skills of patients, Blarcamesine seem to address the disease as understood by now, not just the symptoms.

The implications from all the parts suggests disease altering therapeutic effects for the patients. The unanswered question is “Would Blarcamesine administered earlier stop the progression of the disease or even reversed it, at least for some?”

Link for full analysis:
https://piotrpeterblog.com/2022/03/16/looking-under-the-hood-of-pdd-phase-2-blarcamsine-results-avxl-anvs/